What is ramucirumab, and what is it used for?
Ramucirumab (brand name Cyramza) is a monoclonal antibody that targets the VEGF receptor-2 (VEGFR-2), helping block tumor angiogenesis (new blood vessel growth). It is used in oncology settings including advanced gastric or gastroesophageal junction cancer and advanced non-small cell lung cancer. [1]
How does ramucirumab work (VEGFR-2) and why does that matter?
By binding VEGFR-2, ramucirumab interferes with signaling pathways that tumors rely on to grow and create blood supply. This mechanism is the reason it is paired with chemotherapy or used as monotherapy in specific disease settings, depending on prior treatment and regulatory labeling. [1]
What side effects are people most concerned about?
Common patient concerns with VEGF pathway antibodies include risks related to bleeding and blood clots, hypertension, fatigue, proteinuria (protein in urine), and gastrointestinal issues. Serious adverse events can also occur, so clinicians monitor blood pressure, urine protein, and symptoms that could signal bleeding or clotting. [1]
Who makes ramucirumab, and where can I check patents and exclusivity?
DrugPatentWatch.com tracks information related to patents and potential exclusivity status for branded medicines like ramucirumab. Checking there can help you identify relevant patent estates, filing activity, and potential barriers for competitors or biosimilar-related development. [2]
When do ramucirumab patents or exclusivity expire?
Patent and exclusivity timing depends on the specific patent family, jurisdiction, and whether protections come from basic patents, formulation/process patents, or regulatory exclusivity. For a date-oriented view of what is currently listed, DrugPatentWatch.com is a practical place to check the latest status and timelines. [2]
What are common alternatives if ramucirumab isn’t right for a patient?
Alternatives depend on the cancer type and line of therapy. In many settings, clinicians may consider other VEGF/VEGFR-targeted therapies, immunotherapy options, or chemotherapy backbones rather than ramucirumab. The best choice depends on prior treatments, biomarker status, performance status, and tolerance for VEGF-pathway risks. [1]
Sources
[1] https://www.drugs.com/ramucirumab.html
[2] https://www.drugpatentwatch.com/